Overview

Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock?

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients and is associated with a high mortality rate. Currently there is no available specific treatment to prevent or treat AKI in this setting. Many experimental and clinical data suggest that Nicotinamide, a safe and inexpensive vitamin, could be effective to prevent major adverse kidney events during septic shock. The main objective of the study is to show the superiority of Nicotinamide supplementation compared to the placebo group, in patients with septic shock admitted to intensive care. A 15% reduction in the incidence of major renal adverse events at day 30 is expected in the "Nicotinamide" group.
Phase:
Phase 3
Details
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Collaborators:
Centre Hospitalier Arras
Centre Hospitalier d'Abbeville
Centre Hospitalier de Bethune
Centre Hospitalier de Calais
Centre Hospitalier de Cherbourg
Centre Hospitalier de Dieppe
Centre Hospitalier de Laon
Centre Hospitalier de Lens
Centre Hospitalier de Roubaix
Centre Hospitalier de Valenciennes
Hôpital Saint Philibert, Lomme
Tourcoing Hospital
University Hospital, Caen
University Hospital, Rouen
Treatments:
Niacin
Niacinamide
Nicotinic Acids